Dr. Shanbao Cai 蔡善保
Chief Physician, Research Professor
Department of Orthopedics, Anhui Provincial Cancer Hospital, Hefei
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of bone and soft tissue tumors, spinal disorders, trauma, joint replacement, and infections.
Dr. Cai holds an MD from Peking University Medical College and completed postdoctoral training at Indiana University, obtaining US medical licensure. Formerly Administrative Director of Bone Disease and Tumor Surgery at Anhui Provincial Cancer Hospital, Dr. Cai has published over 20 SCI-indexed papers. Research focuses on bone and soft tissue tumors, supported by National Natural Science Foundation grants.
Professional roles
- Member, Orthopedics Branch of the Chinese Medical Association
- Leader, Anhui Bone Disease and Bone Tumor Group, Chinese Medical Doctor Association
- National Member, Orthopedic Disease Prevention and Control Committee, China International Exchange and Promotion Association for Medical and Health Care
- National Member, Limb Salvage Group, Sarcoma Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Cai Shanbao). Papers usually list the name as Shanbao Cai or Cai S.
Selected publications
13 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Cell Int, 2026 (senior author): Retraction Note: MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene. PubMed 42522005
- Front Oncol, 2021 (senior author): Long Noncoding RNA DICER1-AS1 Functions in Methylation Regulation on the Multi-Drugresistance of Osteosarcoma Cells via miR-34a-5p and GADD45A. PubMed 34307152
- Cancer Cell Int, 2017 (senior author): MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene. PubMed 29118673
- Sci Rep, 2017 (senior author): MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. PubMed 28281638
- BMC Cancer, 2017 (senior author): The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. PubMed 28073349
- Cancer Cell Int, 2016 (senior author): MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene. PubMed 27499703
- Oncotarget, 2016 (senior author): MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene. PubMed 27056900
- Clin Exp Metastasis, 2016 (senior author): MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively. PubMed 26913720
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion